Oral Inosine Does Not Slow Progression of Early Parkinson Disease
No significant difference seen in rate of clinical disease progression or in secondary efficacy outcomes versus placebo
Parkinson Disease
MPR Weekly Dose Podcast Episode 87
This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there’s a new treatment approved for Progressive Familial Intrahepatic Cholestasis.
Stem Cell Therapy Gets Fast Track Status for Parkinson Disease
DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease.
Benefits of Deep Brain Stimulation Persist in Parkinson Disease
Reductions in time spent with dyskinesia, time spent in the off state, and in dopaminergic drugs sustained for more than 15 years.
NeuroSphere Virtual Clinic Allows for Remote Neuromodulation Therapy Management
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
Certain Prostate Drugs Tied to Risk for Parkinson Disease
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
Gocovri Approved to Treat Off Episodes in Parkinson Disease
Results from both studies showed there was a significant increase in “on” time without troublesome dyskinesia, and a significant decrease in “off” time.
Kynmobi Now Available to Treat Off Episodes in Parkinson Disease
Apomorphine is believed to treat off episodes associated with PD through stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.
Plasma Caffeine Concentration Lower in Parkinson Disease
Results similar for caffeine metabolites and non-xanthine marker for coffee consumption in plasma.
New Drug Application for Apomorphine Infusion Pump Submitted for Review
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study.
